How to navigate EU MAA Regulations and Registration Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter this market it is critical to ass...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
How COVID-19 has changed pharmacovigilance
Dr Andrew Garrett contributes to this article in Pharmafocus: How COVID-19 has changed pharmacovigilance. The article explores how drug safety can be ensured while numerous vaccines and treatments come to market in record time to deal with COVID-19.
-
How scientists John Climax and Dr Ronan Lambe created an icon
An article reporting on the growth of ICON as it acquires PRA Health Sciences.
-
-
ICON CEO on PRA deal: Groundwork laid for faster trials (Radio)
A radio intervew with ICON CEO Steve Cutler about the ICON-PRA Health Sciences deal, which is the largest healthcare transaction this year at $12 billion.
-
ICON to acquire PRA for $12B as COVID-19 spurs CRO consolidation
ICON has agreed to acquire PRA Health Sciences for approximately $12 billion in cash and stock, in a deal that continues the consolidation of contract research organisations into a handful of corporate giants.
-
-
Breakfast Business (6.30am show, 13:44 mark)
An interview with ICON CFO Brendan Brennan on ICON’s $12B acquisition of PRA Health Sciences.
-
COVID researchers ICON, PRA Health join in $12 billion deal
ICON agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials.
-
ICON eyes growing virtual clinical trial market with $12 billion PRA Health deal
ICON will buy rival PRA Health Sciences Inc in a deal valued at about $12 billion, to create a contract drug research firm that can tap into the growing demand for virtual clinical trials due to the pandemic.
-
ICON to buy clinical trial rival PRA in $12 billion deal
In acquiring PRA, ICON would expand into digital and technology capabilities that are playing roles in clinical trials accelerated by the Covid-19 pandemic, such as virtual monitoring of study subjects as people stay at home and avoid public places.
